|
KMID : 0366220150500020097
|
|
Korean Journal of Hematology
2015 Volume.50 No. 2 p.97 ~ p.102
|
|
|
Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma
|
|
Jang Hee-Ryeong
Song Moo-Kon
Chung Joo-Seop
Yang Deok-Hwan
Lee Jeong-Ok
Hong Jun-Shik
Cho Su-Hee
Kim Seong-Jang
Shin Dong-Hoon
Park Young-Joo
Kang Jin-Suk
Lee Jeong-Eun
Lee Moon-Won
Shin Ho-Jin
|
|
|
Abstract
|
|
|
Background: Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy.
Methods: A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age ≥ 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] ＜6.0 on PET/CT, time to relapse ≥12 months, complete response after salvage therapy). A low aa-IPI, SUVmax ＜6.0, and time to relapse ≥ 12 months were independent prognostic factors for survival.
Results: In univariate analysis and multivariate analysis, SUVmax below 6.0 (P＜0.001 for progression-free survival (PFS), P＜0.001 for overall survival (OS)) and low aa-IPI (P＜0.001 for PFS, P＜0.001 for OS) were independent prognostic factors associated with favorable outcome.
Conclusion: The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL.
|
|
|
KEYWORD
|
|
|
Positron emission tomography, SUVmax, aa-IPI
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|